UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

April 10, 2006
Date of Report (Date of earliest
event reported)

 

PRAECIS PHARMACEUTICALS INCORPORATED

(Exact Name of Registrant as Specified in Charter)

 

 

830 Winter Street, Waltham, Massachusetts 02451-1420
(Address of principal executive offices, including zip code)

 

(781) 795-4100

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 7.01.                  Regulation FD Disclosure.

 

On April 10, 2006, PRAECIS PHARMACEUTICALS INCORPORATED issued a press release announcing that it has signed a pilot study and option agreement with GlaxoSmithKline, through GlaxoSmithKline's recently established Center of Excellence for External Drug Discovery.

 

Item 9.01.                  Financial Statements and Exhibits.

 

(c)           Exhibits.

 

Exhibit 99.1                                    Press Release issued by PRAECIS PHARMACEUTICALS INCORPORATED on April 10, 2006.

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  April 10, 2006		PRAECIS PHARMACEUTICALS INCORPORATED
		By	/s/ Edward C. English
		Edward C. English
		Vice President, Chief Financial Officer, Treasurer and Assistant Secretary

 

3

 

EXHIBIT INDEX

 

Exhibit Number		Description
99.1		Press Release issued by PRAECIS PHARMACEUTICALS INCORPORATED on April 10, 2006.

 

4